Texas A&M researchers discover mechanism Covid 19 uses to effectively

1,814 Views | 7 Replies | Last: 3 yr ago by Buying_time
SBISA Victim
How long do you want to ignore this user?
AG
escape immune systems.

https://www.kwtx.com/2021/12/16/texas-am-researchers-discover-covid-19-mechanism-that-helps-it-escape-immune-system/

Quote:

COLLEGE STATION, Texas (KBTX) - Researchers at Texas A&M have recently discovered a mechanism in COVID-19 that explains how it can escape our immune systems and replicate so intensely in the human body.

It's been well-known for some time now that COVID-19 causes much more significant illness than other coronaviruses. A team of researchers at Texas A&M, led by Texas A&M Department of Microbial Pathogenesis and Immunology Professor Koichi Kobayashi, say they've found the protein in COVID-19 that is able to suppress that gene and make it harder for the body to detect.

"What we found is that the virus has the ability to decrease the amount of NLRC5 and also it suppresses the function of NLRC5," Kobayashi said.

NLRC5 is a gene in cells that helps control virus infection so it is unable to replicate. It determines the amount of another gene known as major histocompatibility complex (MHC) class I genes that create a pathway for ridding the body of viruses. Kobayashi says MHC class I genes help our body with longer term immunity in the days after infection, as opposed to the hours.


Quote:

"Every cell has MHC class I, and if they are infected, viral antigen is presented on the MHC class I," Kobayashi said. "That means that immune cell can't see it and the infected cell can't be recognized by our immune system."

Kobayashi, who is also a professor at Hokkaido University in Japan, says COVID patients have a normal level of MHC class I, but the level of MHC class I should be boosted when someone is infected by a pathogen.

"I'm hoping that because we found the mechanism, we can modify this so that we can have a little bit of a boost in our immune system to fight off the virus," Kobayashi said. "The patient may be cured quicker than normal, and we also may be able to prevent the severe case."

"The potential is you could find a drug that would hinder this protein, and by hindering this protein, it would allow the body's immune system to function more effectively and rid our bodies of the infection more quickly," CapRock Health System Chief Medical Officer Dr. Long Young said.
rhutton125
How long do you want to ignore this user?
AG
Impressive
aggiebrad94
How long do you want to ignore this user?
AG
This seems like good news.

Then the last two paragraphs read like an ad for vaccines and hopelessness.
ttu_85
How long do you want to ignore this user?
SBISA Victim said:

escape immune systems.

https://www.kwtx.com/2021/12/16/texas-am-researchers-discover-covid-19-mechanism-that-helps-it-escape-immune-system/

Quote:

COLLEGE STATION, Texas (KBTX) - Researchers at Texas A&M have recently discovered a mechanism in COVID-19 that explains how it can escape our immune systems and replicate so intensely in the human body.

It's been well-known for some time now that COVID-19 causes much more significant illness than other coronaviruses. A team of researchers at Texas A&M, led by Texas A&M Department of Microbial Pathogenesis and Immunology Professor Koichi Kobayashi, say they've found the protein in COVID-19 that is able to suppress that gene and make it harder for the body to detect.

"What we found is that the virus has the ability to decrease the amount of NLRC5 and also it suppresses the function of NLRC5," Kobayashi said.

NLRC5 is a gene in cells that helps control virus infection so it is unable to replicate. It determines the amount of another gene known as major histocompatibility complex (MHC) class I genes that create a pathway for ridding the body of viruses. Kobayashi says MHC class I genes help our body with longer term immunity in the days after infection, as opposed to the hours.



Quote:

"Every cell has MHC class I, and if they are infected, viral antigen is presented on the MHC class I," Kobayashi said. "That means that immune cell can't see it and the infected cell can't be recognized by our immune system."

Kobayashi, who is also a professor at Hokkaido University in Japan, says COVID patients have a normal level of MHC class I, but the level of MHC class I should be boosted when someone is infected by a pathogen.

"I'm hoping that because we found the mechanism, we can modify this so that we can have a little bit of a boost in our immune system to fight off the virus," Kobayashi said. "The patient may be cured quicker than normal, and we also may be able to prevent the severe case."

"The potential is you could find a drug that would hinder this protein, and by hindering this protein, it would allow the body's immune system to function more effectively and rid our bodies of the infection more quickly," CapRock Health System Chief Medical Officer Dr. Long Young said.

Corona Viruses Sar1 and Mers say hold my 30%+ death rate beers. Thank God they are not very communicable.

So COVID-19, a member of fairly common family of airborne repository viruses, is believed sourced from Chinese bat **** behaves like HIV. Yeah sure this thing is natural. No way China had anything to do with this. And how this thing mutates Alpha <<< Delta <<<<< Omicron in communicability. Thats natural too.

Thank God Sars1 and MERS never mutate.

AgResearch
How long do you want to ignore this user?
AG
Probably found the microscopic "Made in China" sticker.
DannyDuberstein
How long do you want to ignore this user?
AG
Yeah, this sounds like something born of gain-of-function work. A feature, not a bug, if you will
SBISA Victim
How long do you want to ignore this user?
AG
ttt what do our resident docs think?
Buying_time
How long do you want to ignore this user?
AG
AgResearch said:

Probably found the microscopic "Made in China" sticker.


With Gain of Function Research Funded by NIH
Refresh
Page 1 of 1
 
×
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.